Search

The ESA mission Comet Interceptor will target an Oort or interstellar comet during its first approach to the Sun. Meanwhile, the Vera Rubin LSST Survey will observe hundreds of active comets per month beyond 4 au from the Sun, where water vapour pressure is expected to be too low to eject dust. We discuss observations of dust tails at heliocentric distances larger than 4 au in order to retrieve the physical parameters driving cometary activity beyond Jupiter by means of a probabilistic tail model, which is consistent with the activity model defining the gas coma parameters due to the sublimation of carbon monoxide, molecular oxygen, methane, ethane, and carbon dioxide since the activity onset at 85 au from the Sun. We find that: (i) All the observed dust tails are consistent with the adopted activity model; (ii) The tail fits depend on three free parameters only, all correlated to the nucleus size; (iii) Tail fits are always improved by anisotropic dust ejection, suggesting activity of Oort nuclei dominated by seasons; (iv) Inbound seasons suggest cometary activity before the ejection of protocomets into the Oort cloud, as predicted by the activity model; (v) Oort nuclei larger than 1 km may be characterized by a fallout up to ≈100 m thick deposited during ≈60 yr inbound; (vi) On the other side, Oort nuclei smaller than 1 km may appear more pristine than Jupiter Family Comets when observed at 1 au from the Sun. [ABSTRACT FROM AUTHOR]

In this work, we aim to characterize the dust motion in the inner coma of comet 67P/Churyumov–Gerasimenko to provide constraints for theoretical 3D coma models. The OSIRIS camera on-board the Rosetta mission was able for the first time to acquire images of single dust particles from inside the cometary coma, very close to the nucleus. We analyse a large number of particles, performing a significant statistic of their behaviour during the post-perihelion period, when the spacecraft covered distances from the nucleus ranging between 80 and 400 km. We describe the particle trajectories, investigating their orientation and finding highly radial motion with respect to the nucleus. Then, from the particle brightness profiles, we derive a particle rotational frequency of ν < 3.6 Hz, revealing that they are slow rotators and do not undergo fragmentation. We use scattering models to compare the observed spectral radiance of the particles with the simulated ones in order to estimate their size, finding values that range from millimetres up to centimetres. The statistics performed in this paper provide useful parameters to constrain the cometary coma dynamical models. [ABSTRACT FROM AUTHOR]

We present new spectral observations using ground-based telescopes of 23 putative V-type asteroids, selected according to colour surveys in the visible from the Moving Objects Catalogue of the Sloan Digital Sky Survey and near-infrared from the Moving Objects VISTA catalogue. 10 asteroids are orbiting in the middle main belt, while five in the outer part of the main asteroid belt. For the observed asteroids, we assign a taxonomical classification and confirm the basaltic nature for 16 of them. The high-quality spectra in the UV range, obtained with the X-Shooter spectrograph at ESO, allowed the identification of the Fe2+ forbidden transition of pyroxene for 10 asteroids. This band is centred at 506.5 nm, and it is diagnostic of the Ca-content in the pyroxene form. We determined a low Fe-content composition for asteroids (2452) Lyot, (5758) Brunini, (7675) Gorizia, (9197) Endo, (22308) 1990 UO4, (36118) 1999 RE135, (66905) 1999 VC160, and (189597) 2000 WG119, and a composition more rich in Fe for asteroids (75661) 2000 AB79 and (93620) 2000 UQ70. We also present a dynamical investigation of V-type asteroids in the middle and outer main belt. The principal finding of these simulations is that the middle and outer V-types are more likely to be associated with some families, which were considered as possibly originated from the break up of a partially or totally differentiated parent body by diverse studies. This reinforces the hypothesis that the identified V-type in the region were not originated from (4) Vesta and that the number of differentiated objects in the middle and outer main belt must have been much larger than previously assumed. [ABSTRACT FROM AUTHOR]

Objectives: Despite the fact that there are individuals who have chronic HIV infection, few studies have investigated ART interruption in this setting. The aim of this study was to evaluate the ability to spontaneously control viral replication during analytical treatment interruption (ATI) in adults with chronic HIV-1 infection, on ART, with suppressed viraemia for >10 years and with a low reservoir.Patients and Methods: This was a prospective, open-label, single-arm, non-randomized, proof-of-concept study (NCT03198325) of subjects with chronic HIV-1 infection, HIV-RNA <50 copies/mL for ≥10 years, without residual viraemia for ≥5 years, CD4+ >500 cells/mm3, HIV-DNA <100 copies/106 PBMCs and without comorbidities or AIDS-defining diseases. Enrolled patients were strictly monitored. The ART regimen in use at ATI was resumed in the case of confirmed viral rebound (CVR, two consecutive HIV-RNA >50 copies/mL). Results are reported as median (IQR).Results: Nine patients underwent ATI. All participants experienced CVR [4.84 (IQR: 3.47-6.47) HIV-RNA log10 copies/mL] after ATI at a median time of 21 days (range 14-56) and restarted ART. After ART resumption, all the subjects achieved HIV-RNA <50 copies/mL in a median of 88 days (range 15-197). No serious adverse event occurred; one subject experienced acute retroviral syndrome. No significant correlation between baseline factors and time to viral rebound was observed, while the magnitude of viral rebound was significantly associated with pre-ART HIV-1 RNA (Spearman r = 0.786, P = 0.036), nadir CD4+ (Spearman r = -0.800, P = 0.010), baseline CD4+ (Spearman r = -0.667, P = 0.049) and years with undetectable viral load (Spearman r = -0.717, P = 0.030).Conclusions: Despite a long period of HIV viral load suppression and a low viral reservoir, early and consistent viral rebound was observed during ATI in all subjects. [ABSTRACT FROM AUTHOR]

We present experimental phase function and degree of linear polarization curves for seven samples of cometary dust analogues namely: ground pieces of Allende, DaG521, FRO95002, and FRO99040 meteorites, Mg-rich olivine and pyroxene, and a sample of organic tholins. The experimental curves have been obtained at the IAA Cosmic Dust Laboratory at a wavelength of 520 nm covering a phase angle range from 3° to 175°. We also provide values of the backscattering enhancement for our cometary analogue samples. The final goal of this work is to compare our experimental curves with observational data of comets and asteroids to better constrain the nature of cometary and asteroidal dust grains. All measured phase functions present the typical behaviour for |$\mu$| m-sized cosmic dust grains. Direct comparison with data provided by the OSIRIS/Rosetta camera for comet 67P/Churyumov–Gerasimenko reveals significant differences and supports the idea of a coma dominated by big chunks, larger than one micrometer. The polarization curves are qualitatively similar to ground-based observations of comets and asteroids. The position of the inversion polarization angle seems to be dependent on the composition of the grains. We find opposite dependence of the maximum of the polarization curve for grains sizes in the Rayleigh-resonance and geometric optics domains, respectively. [ABSTRACT FROM AUTHOR]

Diel stem diameter changes measured at the stem base of temperate tree species can be mostly explained by a hydraulic system of flow and storage compartments passively driven by transpiration. Active, osmotic processes are considered to play a minor role only. Here we explore whether such osmotic processes have a stronger impact on diel changes in twig diameter than in stem diameter because twigs are closer to the leaves, the main source of newly acquired carbon. We investigated stem and twig diameter changes of wood and bark of pine trees in parallel to fluctuations of the osmolality in needles and in the bark at the stem base. We found consistent twig bark size increments concurrent with twig wood size decreases during daylight hours whereas needle osmolality was not consistently increasing even on sunny days. The size changes of bark and wood either reversed or ran in parallel from late afternoon onwards until the next morning. No such patterns were measurable at the stem base. Stem wood was hardly changing in size, whereas stem bark followed the regular pattern of a decrease during the daylight hours and an increase during the night. Osmolality at the stem base showed no particular course over 24 h. We conclude that assimilates from the needles were rapidly transported to the twigs where they increased the osmolality of the bark tissue by sugar loading, explaining the bark size increase (over-) compensating the xylem size decrease. The stem base largely followed the expectation of a passive, hydraulic system without a measurable role of osmoregulation. Diameter changes thus follow different diurnal dynamics in twigs and at the stem base. [ABSTRACT FROM AUTHOR]

Remote sensing observations of dust particles ejected from comets provide important hints on the intimate nature of the materials composing these primitive objects. The measurement of dust coma backscattering ratio, BSR, defined as the ratio of the reflectance at phase angle 0° and 30°, helps tuning theoretical models aimed at solving the inverse scattering problem deriving information on the nature of the ejected particles. The Rosetta /OSIRIS camera sampled the coma phase function of comet 67P, with four series acquired at low phase angles from 2015 January to 2016 May. We also added previously published data to our analysis to increase the temporal resolution of our findings. We measured a BSR in the range ∼ [1.7–3.6], broader than the range found in literature from ground-based observations of other comets. We found that during the post-perihelion phase, the BSR is systematically larger than the classical cometary dust values only for nucleocentric distances smaller than ∼100 km. We explain this trend in terms of a cloud of chunks orbiting the nucleus at distances <100 km ejected during perihelion and slowly collapsing on the nucleus over a few months because of the coma gas drag. This also implies that the threshold particle size for the dust phase function to become similar to the nucleus phase function is between 2.5 mm and 0.1 m, taking into account previous Rosetta findings. [ABSTRACT FROM AUTHOR]

Between 2014 and 2016, ESA’s Rosetta OSIRIS cameras acquired multiple-filters images of the layered nucleus of comet 67P/Churyumov–Gerasimenko, ranging from ultraviolet to near-infrared wavelengths. No correlation between layers disposition and surface spectral variegation has been observed so far. This paper investigates possible spectral differences among decametre-thickness outcropping layers of the biggest lobe of the comet by means of OSIRIS image dataset. A two-classes maximum likelihood classification was applied on consolidated outcrops and relative deposits identified on post-perihelion multispectral images of the big lobe. We distinguished multispectral data on the basis of the structural elevation of the onion-shell Ellipsoidal Model of 67P. The spatial distribution of the two classes displays a clear dependence on the structural elevation, with the innermost class resulting over 50 per cent brighter than the outermost one. Consolidated cometary materials located at different structural levels are characterized by different brightness and revealed due to the selective removal of large volumes. This variegation can be attributed to a different texture of the outcrop surface and/or to a different content of refractory materials. [ABSTRACT FROM AUTHOR]

Background. Progressive multifocal leukoencephalopathy (PML) is a severe demyelinating disease caused by the polyomavirus JC (John Cunningham; JCV) that affects patients with impaired immune systems. While JCV-DNA detection in cerebrospinal fluid (CSF) is diagnostic of PML, the clinical significance of plasma JCV-DNA is uncertain. Methods. We retrospectively analyzed plasma samples from PML patients that were drawn close to disease onset and from controls without PML. In PML patients, we compared plasma JCV-DNA detection and levels to clinical and laboratory parameters, and patient survival. Results. JCV-DNA was detected in plasma of 49/103 (48%) patients with PML (20/24, 83%, human immunodeficiency virus [HIV] negative; 29/79, 37%, HIV-positive) and of 4/144 (3%) controls without PML (0/95 HIV-negative; 4/49, 8%, HIV-positive), yielding a diagnostic sensitivity and specificity of 48% and 97% (83% and 100% in HIV-negative; 37% and 92% in HIV-positive), respectively. Among 16 PML patients with undetectable CSF JCV-DNA, 4 (25%) had detectable plasma JCV-DNA. Plasma JCV-DNA levels were independently associated with CSF levels (P < .0001) and previous corticosteroid treatment (P = .012). Higher plasma JCV-DNA levels were associated with disease progression in HIV-negative patients (P = .005); in HIV-positive patients, there was an increased risk of progression only in those treated with combination antiretroviral therapy (cART; P < .0001). Conclusions. Testing JCV-DNA in plasma might complement PML diagnosis, especially when CSF is unavailable or JCV-DNA not detectable in CSF. In addition, JCV-DNA plasma levels could be useful as a marker of disease progression in both HIV-negative and cART-treated, HIV-positive PML patients. [ABSTRACT FROM AUTHOR]

PhotoVoltaic/Thermal cogeneration (PV/T) aims to utilize the same area both for producing electricity and heat. An electric compression heat pump can be coupled to the PV/T panels to contribute to the space heating demand partially using the self-produced electricity. Some Italian climates and economic incentives scenarios are considered with Trnsys simulations to evaluate the energy and economic viability of PV/T-heat pump hybrid technology. Primary energy saving results to be between 35% and 65%, and discounted payback of the investment can be around 10 years in mild climates and southern resorts. [ABSTRACT FROM AUTHOR]

Objectives: This study evaluated the virological efficacy of dolutegravir 50 mg twice daily in 190 HIV-1 failing antiretroviral-experienced patients with previous exposure to first-generation integrase strand transfer inhibitor (INSTI) over a 5 year follow-up using data from clinical practice.Patients and Methods: This analysis included HIV-1-infected patients who were ≥18 years of age, treatment experienced, had HIV-1 RNA >50 copies/mL, with INSTI-resistant virus, who started dolutegravir 50 mg twice daily plus optimized background therapy (OBT), recorded in the national prospective database PRESTIGIO (www.progettoprestigio.it). Follow-up accrued from the start of dolutegravir 50 mg twice daily + OBT until virological failure (VF) or dolutegravir discontinuation for any reason or the last treatment visit on dolutegravir 50 mg twice daily treatment. VF was defined by the lack of achievement of HIV-1 RNA <50 copies/mL by 6 months and thereafter, or the occurrence of two consecutive HIV-1 RNA ≥50 copies/mL after achievement of undetectable viral load.Results: The estimated VF probabilities were 17% (95% CI = 12%-24%), 28% (95% CI = 21%-37%), 33% (95% CI = 25%-43%), 39% (95% CI = 29%-51%) and 52% (95% CI = 39%-67%) at 12, 24, 36, 48 and 60 months since baseline, respectively. A higher risk of VF was independently associated with baseline viral load >100000 copies/mL (adjusted HR = 4.73, 95% CI = 1.33-16.78, P = 0.016) and with ≥1 INSTI mutations plus Q148H/K/R/N and the G140S/A/C as compared with other subjects (adjusted HR = 4.18, 95% CI = 1.32-13.23, P = 0.015).Conclusions: Our data showed a favourable long-term efficacy of dolutegravir 50 mg twice daily in association with OBT in treatment-experienced failing subjects, with INSTI-resistant virus, in the real world. A close monitoring of adherence is crucial for maintenance of virological response in this fragile subgroup of subjects. [ABSTRACT FROM AUTHOR]

Though in a foundry most of the energy is used in the process plants and particularly in energizing furnaces, service plants require absolutely large amounts of energy, above all as electricity. The most energy-consuming service is compressed air preparation, but large amounts are due to lighting, heating, ventilation and air conditioning, pumps and fans. These energy users are common to most of the industrial branches with different weights both in absolute and relative terms. This article reports on the experience of some energy audits carried out in five Italian cast iron foundries allowing to identify the relative importance of different services in this industrial branch. The analysis is based on real data measured during the audits. Energy saving actions were then conceived, comparing the results of new technologies applied in some factory sectors and the energy usage of the previous equipment. [ABSTRACT FROM AUTHOR]

Background. Ombitasvir, paritaprevir with ritonavir, and dasabuvir (OBV/PTV/r ± DSV) ±ribavirin (RBV) are approved to treat hepatitis C virus (HCV) genotype 1 and 4 infection. Here, we investigate the safety and efficacy of OBV/PTV/r + DSV ±RBV for HCV genotype 1, and OBV/PTV/r + RBV for HCV genotype 4, in human immunodeficiency virus (HIV)-1 coinfected patients with or without compensated cirrhosis. Methods. TURQUOISE-I, Part 2 is a phase 3 multicenter study. Patients with or without cirrhosis were HCV treatment-naive or -experienced, on an HIV-1 antiretroviral regimen containing atazanavir, raltegravir, dolutegravir, or darunavir (for genotype 4 only), and had plasma HIV-1 ribonucleic acid <40 copies/mL at screening. Patients received OBV/PTV/r ± DSV ±RBV for 12 or 24 weeks. Results. In total, 228 patients were treated according to guidelines. Sustained virologic response at posttreatment week 12 (SVR12) was achieved by 194 of 200 (97%) and 27 of 28 (96%) patients with HCV genotype 1 and genotype 4 infection, respectively. There were 2 virologic failures: 1 breakthrough and 1 relapse in a cirrhotic and a noncirrhotic patient with genotype 1b and 1a infection, respectively. One reinfection occurred at posttreatment week 12 in a genotype 1a-infected patient. Excluding nonvirologic failures, the SVR12 rates were 98% (genotype 1) and 100% (genotype 4). Adverse events were mostly mild in severity and did not lead to discontinuation. Laboratory abnormalities were rare. Conclusions. The OBV/PTV/r ±DSV was well tolerated and yielded high SVR12 rates in patients with HCV genotype 1 or genotype 4/HIV-1 coinfection. The OBV/PTV/r ± DSV ±RBV is a potent HCV treatment option for patients with HIV-1 coinfection, regardless of treatment experience. [ABSTRACT FROM AUTHOR]

Objectives: To evaluate the plasma trough concentrations ( C trough ) of dolutegravir and rilpivirine used in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus (HCV)-coinfected patients with liver cirrhosis. Virological efficacy and safety of both ART and anti-HCV therapy were assessed.Patients and methods: A prospective observational study in HIV/HCV-coinfected patients with liver cirrhosis on ART with dolutegravir plus rilpivirine and treated with simeprevir plus sofosbuvir (±ribavirin) was conducted. Dolutegravir, rilpivirine, GS-331007 (sofosbuvir metabolite) and simeprevir C trough were evaluated with a validated HPLC method at anti-HCV treatment baseline and weeks 2 and 4. Geometric means were calculated to summarize C trough values.Results: Twelve patients were evaluated: 75% were males and the median (IQR) age was 53 (53-55) years. All patients were Child-Pugh stage A, except one who was stage B. The geometric mean (95% CI) of C trough of rilpivirine and dolutegravir did not change between baseline and week 4 ( P  =   0.654 and P  =   0.268, respectively), with corresponding overall values of 135 (102-177) and 1357 (970-1897) ng/mL. The overall geometric mean (95% CI) of GS-331007 and simeprevir C trough was 370 (268-512) and 2537 (1569-4101) ng/mL, respectively, without significant variation between weeks 2 and 4 ( P  =   0.643 and P  =   0.179, respectively). All patients completed anti-HCV treatment, achieving sustained virological response. All but two patients maintained undetectable HIV-RNA up to post-treatment week 24.Conclusions: Dolutegravir and rilpivirine C trough appeared not to be affected by concomitant treatment with simeprevir plus sofosbuvir in these HIV/HCV-coinfected patients with liver cirrhosis, supporting the use of this antiretroviral regimen in this setting. [ABSTRACT FROM AUTHOR]

Background. While liver-related deaths in human immunodeficiency virus (HIV) and hepatitis C virus (HCV)-coinfected individuals have declined over the last decade, hepatocellular carcinoma (HCC) may have increased. We describe the epidemiology of HCC and other liver events in a multicohort collaboration of HIV/HCV-coinfected individuals. Methods. We studied HCV antibody-positive adults with HIV in the EuroSIDA study, the Southern Alberta Clinic Cohort, the Canadian Co-infection Cohort, and the Swiss HIV Cohort study from 2001 to 2014. We calculated the incidence of HCC and other liver events (defined as liver-related deaths or decompensations, excluding HCC) and used Poisson regression to estimate incidence rate ratios. Results. Our study comprised 7229 HIV/HCV-coinfected individuals (68% male, 90% white). During follow-up, 72 cases of HCC and 375 other liver events occurred, yielding incidence rates of 1.6 (95% confidence interval [CI], 1.3, 2.0) and 8.6 (95% CI, 7.8, 9.5) cases per 1000 person-years of follow-up, respectively. The rate of HCC increased 11% per calendar year (95% CI, 4%, 19%) and decreased 4% for other liver events (95% CI, 2%, 7%), but only the latter remained statistically significant after adjustment for potential confounders. Older age, cirrhosis, and low current CD4 cell count were associated with a higher incidence of both HCC and other liver events. Conclusions. In HIV/HCV-coinfected individuals, the crude incidence of HCC increased from 2001 to 2014, while other liver events declined. Individuals with cirrhosis or low current CD4 cell count are at highest risk of developing HCC or other liver events. [ABSTRACT FROM AUTHOR]

Objectives: To report the 96 week results on efficacy, safety and bone mineral density (BMD) in subjects with HIV-1 that were virologically suppressed and treated with atazanavir/ritonavir monotherapy versus atazanavir/ritonavir triple therapy.Methods: MODAt is a prospective, multicentre, open-label, non-inferiority, randomized, 96 week trial (NCT01511809) comparing efficacy of atazanavir/ritonavir monotherapy versus atazanavir/ritonavir triple therapy. Treatment success was defined as no occurrence of confirmed viral rebound (two consecutive HIV-RNA >50 copies/mL) or discontinuation for any cause of the ongoing regimen.Results: The 96 week treatment success was 64% in the atazanavir/ritonavir monotherapy arm and 63% in the triple-therapy arm (difference 1.3%, 95% CI: -17.5 to 20.1). In the atazanavir/ritonavir monotherapy arm, no PI- or NRTI-associated resistance mutations were observed at virological failure and all patients re-suppressed after re-intensification. In the monotherapy arm, treatment failure was more frequent in patients coinfected with hepatitis C virus [64% versus 28% (difference 35.4%, 95% CI: 3.7-67.2)]. Drug-related adverse events leading to discontinuation were 3 (6%) in the atazanavir/ritonavir monotherapy arm and 11 (21.5%) in the triple-therapy arm (P = 0.041). The 96 week adjusted mean percentage change in total proximal femur (not at lumbar spine) BMD was +1.16% and -1.64% in the atazanavir/ritonavir monotherapy arm and the triple-therapy arm, respectively (P = 0.012).Conclusions: The 96 week analyses suggested that long-term efficacy of atazanavir/ritonavir monotherapy was inferior as compared with atazanavir/ritonavir triple therapy, particularly when administered in subjects coinfected with hepatitis C virus. In the atazanavir/ritonavir monotherapy arm, reintroduction of nucleosides, as needed, was always effective with no new resistance mutation; monotherapy was also associated with a lower incidence of adverse events and improvement in femur BMD. [ABSTRACT FROM AUTHOR]

Background: After the advent of ART, non-AIDS-related comorbidities are the main causes of death in HIV patients. Multiple biomarkers have been studied as markers of disease. We wanted to test soluble endothelial protein C receptor (sEPCR) in an HIV setting.Objectives: The primary objective was to determine whether sEPCR decreases after 48 weeks of ART in naive HIV patients. Secondary objectives were to compare sEPCR levels between patients with chronic HIV infection (CHI) and primary HIV infection (PHI) and to analyse if there is a correlation between sEPCR and both immunovirological parameters and different markers of inflammation.Patients and Methods: We analysed sEPCR in 33 patients with CHI and 19 patients with PHI naive to ART. sEPCR was compared together with immunovirological parameters (HIV RNA and CD4 cell count) and IL-6 or D-dimer (DD).Results and Conclusions: After 48 weeks of ART, in CHI, the sEPCR decrease was significant (P = 0.0006) and sEPCR at baseline was correlated with both CD4 cell increase (r = +0.463, P = 0.007) and HIV RNA decrease (r = -0.363, P = 0.038). In PHI, sEPCR was stable (P = 0.35); there was a correlation between 48 week DD change and IL-6 change (r = +0.696, P = 0.0009) and also between 48 week DD change and sEPCR change (r = +0.553, P = 0.014). Despite the small sample size, we hypothesize that sEPCR levels reflect coagulant pathway activation caused by the endothelial damage during chronic infection more than a marker of the cytokine storm that occurs during PHI. Alternatively, in PHI, the link found between sEPCR and DD secondary to IL-6 suggests sEPCR is an indirect marker of inflammation. [ABSTRACT FROM AUTHOR]

Objectives: Although founder viruses in primary HIV-1 infections (PHIs) typically use the CCR5 coreceptor (R5- tropic), 3%-19% of subjects also harbour CXCR4-using viruses (X4-tropic), making tropism determination before CCR5 antagonist usage mandatory. Genotypic methods can be used to accurately determine HIV-1 tropism in chronically infected patients. Methods: We compared the results of genotypic methods [geno2pheno, PSSMx4r5 including a novel nucleotideinput version (ntPSSM) and distant segments (ds)Kernel] to predict coreceptor usage in a cohort of 67 PHIs. Specimens with discrepant results were phenotypically tested after cloning the V3 gene region into proviral backbones. Recombinant viruses were used to infect U87 indicator cell lines bearing CD4 and either CCR5 or CXCR4. Results: Geno2pheno10%, PSSMx4r5 and (ds)Kernel gave identical predictions in 85% of cases. Geno2pheno10% predicted the presence of CXCR4 viruses in 18% of patients. Two patients were predicted to carry X4-tropic viruses by all algorithms and X4-tropic viruses were detected in at least one of the recombinant AD8 or NL4-3 backbonebased assays. Ten samples resulted in discordant predictions with at least one algorithm. Full concordance between tropism prediction by using population sequencing and phenotypic assays was observed only with ntPSSM. Geno2pheno prediction and the phenotypic assay gave the same results in a minority of 'discordant' patients. Conclusions: Compared with both PSSMx4r5 versions, (ds)Kernel and our phenotypic assay, geno2pheno10% overestimated the frequency of X4-tropic viruses (18% versus 3%). ntPSSM was able to detect one additional X4 virus compared with (ds)Kernel that was confirmed with the phenotypic assay. [ABSTRACT FROM AUTHOR]

The CC chemokine monocyte chemotactic protein-1 (MCP-1) was markedly elevated in the cerebrospinal fluid (CSF) of human immunodeficiency virus (HIV)-infected patients with cytomegalovirus (CMV) encephalitis. The MCP-1 CSF levels in CMV encephalitis were markedly higher than those in the CSF of HIV-infected patients with or without unrelated neurologic diseases, including progressive multifocal leukoencephalopathy, cryptococcal meningitis, toxoplasmic encephalitis, and primary lymphoma. Interleukin-8, RANTES, macrophage inflammatory protein (MIP)-1 alpha, and MIP-1 beta were not substantially increased in the CSF of CMV encephalitis patients. High levels of MCP-1 may underlie monocyte recruitment and tissue damage in CMV encephalitis and may represent a rapid and useful tool in the diagnostic armamentarium for neurologic disorders associated with HIV infection. [ABSTRACT FROM AUTHOR]

A letter to the editor is presented discussing a study on the association between plasma fibroblast growth factor 23 and osteocalcin serum levels with cardiovascular risk in HIV-1-infected patients undergoing antiretroviral treatment.

Objectives: The cross-resistance profiles of elvitegravir and dolutegravir on raltegravir-resistant variants is still controversial or not available in macrophages and lack extensive evaluations on wide panels of clonal variants. Thus, a complete evaluation in parallel with all currently available integrase inhibitors (INIs) was performed.Methods: The integrase coding region was RT-PCR-amplified from patient-derived plasma samples and cloned into an HIV-1 molecular clone lacking the integrase region. Twenty recombinant viruses bearing mutations to all primary pathways of resistance to raltegravir were phenotypically evaluated with each integrase inhibitor in freshly purified CD4+ T cells or monocyte-derived macrophages.Results: Y143R single mutants conferred a higher level of raltegravir resistance in macrophages [fold change (FC) 47.7-60.24] compared with CD4+ T cells (FC 9.55-11.56). All other combinations had similar effects on viral susceptibility to raltegravir in both cell types. Elvitegravir displayed a similar behaviour both in lymphocytes and macrophages with all the tested patterns. When compared with raltegravir, none to modest increases in resistance were observed for the Y143R/C pathways. Dolutegravir maintained its activity and cross-resistance profile in macrophages. Only Q148H/R variants had a reduced level of susceptibility (FC 5.48-18.64). No variations were observed for the Y143R/C (+/-T97A) or N155H variants.Conclusions: All INIs showed comparable antiretroviral activity in both cell types even if single mutations were associated with a different level of susceptibility in vitro to raltegravir and elvitegravir in macrophages. In particular, dolutegravir was capable of inhibiting with similar potency infection of raltegravir-resistant variants with Y143 or N155 pathways in both HIV-1 major cell reservoirs. [ABSTRACT FROM AUTHOR]

Heat pump features can take advantage of better sources than air, for instance the ground heat, solar heat and heat recovery. A multisource system aims to enhance the performances of the heat pump, leading to a significant amount of primary energy being saved. The present work shows data monitoring and analysis for a real working application in northern Italy, for 12 months. The energy balance indicates that the integration of different sources not only increases the thermal performance of the system as a whole but also optimizes the use of each source. [ABSTRACT FROM AUTHOR]

Background: Dolutegravir (DTG; S/GSK1349572), a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, has limited cross-resistance to raltegravir (RAL) and elvitegravir in vitro. This phase IIb study assessed the activity of DTG in HIV-1-infected subjects with genotypic evidence of RAL resistance.Methods: Subjects received DTG 50 mg once daily (cohort I) or 50 mg twice daily (cohort II) while continuing a failing regimen (without RAL) through day 10, after which the background regimen was optimized, when feasible, for cohort I, and at least 1 fully active drug was mandated for cohort II. The primary efficacy end point was the proportion of subjects on day 11 in whom the plasma HIV-1 RNA load decreased by ≥0.7 log(10) copies/mL from baseline or was <400 copies/mL.Results: A rapid antiviral response was observed. More subjects achieved the primary end point in cohort II (23 of 24 [96%]), compared with cohort I (21 of 27 [78%]) at day 11. At week 24, 41% and 75% of subjects had an HIV-1 RNA load of <50 copies/mL in cohorts I and II, respectively. Further integrase genotypic evolution was uncommon. Dolutegravir had a good, similar safety profile with each dosing regimen.Conclusion: Dolutegravir 50 mg twice daily with an optimized background provided greater and more durable benefit than the once-daily regimen. These data are the first clinical demonstration of the activity of any integrase inhibitor in subjects with HIV-1 resistant to RAL. [ABSTRACT FROM AUTHOR]

ABSTRACT The Martian satellite Phobos has been observed on 2007 February 24 and 25, during the pre- and post-Mars closest approach (CA) of the ESA Rosetta spacecraft Mars swing-by. The goal of the observations was the determination of the surface composition of different areas of Phobos, in order to obtain new clues regarding its nature and origin. Near-ultraviolet, visible and near-infrared (263.5-992.0 nm) images of Phobos's surface were acquired using the Narrow Angle Camera of the OSIRIS instrument onboard Rosetta. The six multi-wavelength sets of observations allowed a spectrophotometric characterization of different areas of the satellite, belonging respectively to the leading and trailing hemisphere of the anti-Mars hemisphere, and also of a section of its sub-Mars hemisphere. The pre-CA spectrophotometric data obtained with a phase angle of 19° have a spectral trend consistent within the error bars with those of unresolved/disc-integrated measurements present in the literature. In addition, we detect an absorption band centred at 950 nm, which is consistent with the presence of pyroxene. The post-CA observations cover from NUV to NIR a portion of the surface (0° to 43°E of longitude) never studied before. The reflectance measured on our data does not fit with the previous spectrophotometry above 650 nm. This difference can be due to two reasons. First, the OSIRIS observed area in this observation phase is completely different with respect to the other local specific spectra and hence the spectrum may be different. Secondly, due to the totally different observation geometry (the phase angle ranges from 137° to 140°), the differences of spectral slope can be due to phase reddening. The comparison of our reflectance spectra, both pre- and post-CA, with those of D-type asteroids shows that the spectra of Phobos are all redder than the mean D-type spectrum, but within the spectral dispersion of other D-types. To complement this result, we performed an investigation of the conditions needed to collisionally capture Phobos in a way similar to that proposed for the irregular satellites of the giant planets. Once put in the context of the current understanding of the evolution of the early Solar system, the coupled observational and dynamical results we obtained strongly argue for an early capture of Phobos, likely immediately after the formation of Mars. [ABSTRACT FROM AUTHOR]

The consumption of natural gas as a primary energy source in Italy has increased during recent years, mainly due to more widespread use of modern natural gas-fired combined cycle power plants. It is generally accepted that such an increased use of natural gas is beneficial, particularly in summer, due to the ‘take-or-pay’ contracts that often regulate energy supply. Conversely, the use of electrical energy should be decreased, in order to limit the ‘peak demand’ problem that has become prevalent in Italy. Therefore, besides electrically driven heat pumps (EHPs) that achieve good efficiencies, it is interesting to also consider the option of combustion engine-driven GEHPs for space heating purposes. In the latter type of HPs, losses attributed to the production and transport of electricity are eliminated and, in addition, there is the possibility to re-use the heat from the combustion engine. This article presents an assessment of the annual economic and energy profiles of electric and internal combustion engine HPs for space heating purposes. Due to the dependency of the performance of such technology on the source and sink (heating circuit) temperature levels, a comparison is performed of air-to-water HP systems (the most widely used) in two cases of maximum flow temperatures. The calculations show that natural gas-driven HPs can achieve approximately the same efficiency as electrically driven HPs that are powered with electricity from modern natural gas-fired combined cycle power plants. Within this study, the efficiencies of such systems are also compared with those that utilize conventional boiler technologies. [ABSTRACT FROM AUTHOR]

Objectives It is currently debated whether patients with residual viraemia are at higher risk of virological failure than those attaining <1 HIV RNA copy/mL. We therefore investigated the effect of residual viraemia on virological rebound. Methods We used a prospective, non-interventional, single-centre, study. This analysis was based on HIV-infected patients with two consecutive HIV RNA viral loads (VLs) of <50 copies/mL as tested by Versant bDNA, followed by two HIV RNA VLs of <50 copies/mL as tested using the Versant kinetic PCR molecular system (kPCR; limit of quantification = 1 copy/mL). Virological rebound was defined as two consecutive HIV RNA values of >50 copies/mL after baseline, and the time to virological rebound was calculated using the Kaplan–Meier method. Results There were 739 eligible patients; 446 (60.4%) had HIV RNA <1 copy/mL (group A) and 293 (39.6%) had residual viraemia (1–49 HIV RNA copies/mL; group B). After a follow-up (median 48.9 weeks), virological rebound occurred in four patients in group A (0.9%) and six patients in group B (2%); the time to virological rebound was similar in the two groups (log-rank test P = 0.231). CD4+ cell recovery (slope) was significantly less in the patients with residual viraemia; +14.3 (−7.7, 43.9) cells/mm3 per year versus +21.2 (−2.5, 53.2) cells/mm3 per year; P = 0.036. Conclusions Residual viraemia assessed by kPCR was not associated with virological rebound during 1 year of follow-up. However, the patients attaining <1 HIV RNA copy/mL showed a small but statistically significant improvement in CD4+ cell recovery. [ABSTRACT FROM PUBLISHER]

Novel integrase inhibitors are in advanced clinical development, and cross-resistance data are needed to consider the possibility to plan a sequential usage within this class of antiretroviral drugs. Ex vivo phenotypic assays were conducted on 11 wild-type and 27 fully replicating recombinant viruses obtained from 11 patients failing previous raltegravir-containing regimens. Dolutegravir maintained its activity in vitro on viruses withmutations in position 143 and 155. However, viruses with mutation Q148R associated with secondarymutations and the combination Q148H+G140S were instead associated with a reduced level of susceptibility to dolutegravir in vitro. [ABSTRACT FROM AUTHOR]

Background. We compared 3 years of antiretroviral therapy with raltegravir or efavirenz as part of a combination regimen in the ongoing STARTMRK study of treatment-naive patients infected with human immunodeficiency virus (HIV). Methods. Eligible patients with HIV-1 RNA (vRNA) levels >5000 copies/mL and without baseline resistance to efavirenz, tenofovir, or emtricitabine were randomized in a double-blind, noninferiority study to receive raltegravir or efavirenz, each combined with tenofovir/emtricitabine. Outcomes included viral suppression, adverse events, and changes from baseline metabolic parameters. Dual energy X-ray absorptiometry scans were obtained on a convenience sample of patients at prespecified time points to assess changes in body fat composition. Results. At week 156 counting noncompleters as failures, 212 (75.4%) of 281 versus 192 (68.1%) of 282 had vRNA levels <50 copies/mL in the raltegravir and efavirenz groups, respectively [Δ (95% CI) 5 7.3% (20.2, 14.7), noninferiority P < .001]. Mean changes from baseline CD4 count were 332 and 295 cells/mm3 in the raltegravir and efavirenz arms, respectively [Δ (95% CI) 5 37 (4, 69)]. Consistent virologic and immunologic efficacy was maintained across prespecified demographic and baseline prognostic subgroups for both treatment groups. Fewer drug-related clinical adverse events (49% vs 80%; P <.001) occurred in raltegravir than efavirenz recipients, with discontinuations due to adverse events in 5% and 7%, respectively. Elevations in fasting lipid levels (including LDL- and HDL-cholesterol) were consistently lower in the raltegravir than efavirenz group (P < .005). Fat gain was 19% in 25 raltegravir recipients and 31% in 32 efavirenz recipients at week 156. Conclusions. When combined with tenofovir/emtricitabine in treatment-naive patients, raltegravir produced durable viral suppression and immune restoration that was at least equivalent to efavirenz through 156 weeks of therapy. Both regimens were well tolerated, but raltegravir was associated with fewer drug-related clinical adverse events and smaller elevations in lipid levels. [ABSTRACT FROM AUTHOR]

Progressive multifocal leukoencephalopathy (PML), a fatal demyelinating disease caused by JC virus (JCV) infection of oligodendrocytes, may develop in patients with immune disorders following reactivation of chronic benign infection. Mutations of JCV capsid viral protein 1 (VP1), the capsid protein involved in binding to sialic acid cell receptors, might favor PML onset.Cerebrospinal fluid sequences from 37/40 PML patients contained one of several JCV VP1 amino acid mutations, which were also present in paired plasma but not urine sequences despite the same viral genetic background. VP1-derived virus-like particles (VLPs) carrying these mutations lost hemagglutination ability, showed different ganglioside specificity, and abolished binding to different peripheral cell types compared with wild-type VLPs. However, mutants still bound brain-derived cells, and binding was not affected by sialic acid removal by neuraminidase. JCV VP1 substitutions are acquired intrapatient and might favor JCV brain invasion through abrogation of sialic acid binding with peripheral cells, while maintaining sialic acid–independent binding with brain cells. [ABSTRACT FROM PUBLISHER]

BACKGROUND Proper maternal thyroid function is necessary for a successful pregnancy. In order to identify women who may experience miscarriage due to transient impairment of the pituitary–thyroid axis in early pregnancy, we aimed to investigate the ratio between basal and peak thyroid stimulating hormone (TSH) [following stimulus with thyrotrophin-releasing hormone (TRH)] in euthyroid women with unexplained recurrent miscarriage (RM). METHODS We have established a ‘iTSHa index' (TSH increase after TRH adjusted for the levels of basal TSH), determining TSH serum levels at time 0 and 20 min after TRH stimulus in 463 consecutive women attending two antenatal care units for two or more miscarriages occurring within the first 10 weeks of pregnancy. RESULTS The mean basal TSH serum levels were higher (P < 0.001) in RM women [2.1 μIU/ml; 95% confidence interval (CI): 2.0–2.2] compared with the controls (1.3 μIU/ml; 95% CI: 1.2–1.4). Establishing serum TSH at an individual level, a large overlap was observed and the receiver operating characteristic curves did not allow us to find an optimal cut-off point with an adequate sensitivity/specificity ratio. Therefore, we suggest a novel statistical model, the ‘iTSHa index' (available on www.afar.it/tsh-trh-miscarriage), that is capable of identifying women with RM due to transient thyroid function impairment of the early pregnancy, in particular when baseline serum TSH is less than 1.5 μIU/ml, i.e. well below the conventional upper cut-off indicated as ‘safe' in those who want to conceive. CONCLUSIONS A transient impairment of thyroid function in early pregnancy may cause an inadequate adaptation to the increased thyroid requirement and may be implicated in RM. The evaluation of the proposed iTSHa index, if validated in a larger cohort of patients, may provide information useful to identifying a subset of healthy women, without evidence of thyroid dysfunction or autoimmunity and a TSH in the low-normal reference range, who may be at risk of RM. [ABSTRACT FROM AUTHOR]

Objectives Estimating the prevalence of accumulated HIV drug resistance in patients receiving antiretroviral therapy (ART) is difficult due to lack of resistance testing at all occasions of virological failure and in patients with undetectable viral load. A method to estimate this for 6498 EuroSIDA patients who were under follow-up on ART at 1 July 2008 was therefore developed by imputing data on patients with no prior resistance test results, based on the probability of detecting resistance in tested patients with similar profiles. Methods Using all resistance test results available, predicted intermediate/high-level resistance to specific drug classes [nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs)] was derived using the Stanford algorithm v5.1.2. Logistic regression models were then employed to estimate predicted probability of resistance to each drug class for given values of current viral load, history of virological failure and previous virological suppression. Based on these predicted probabilities and patients’ covariate profiles, estimates of prevalence in 5355 patients with no prior test results were obtained. Overall prevalence of resistance was estimated by pooling these data with those observed in the remaining 1143 tested patients. Results Prevalence of NRTI, NNRTI and PI resistance was estimated as 43% (95% confidence interval: 39%–46%), 15% (13%–18%) and 25% (22%–28%), respectively. Conclusions This method provides estimates for the proportion of treated patients in a cohort who harbour resistance on a given date, which are less likely to be affected by selection bias due to missing resistance data and will allow us to estimate prevalence of resistance to different drug classes at specific timepoints in HIV-infected populations on ART. [ABSTRACT FROM PUBLISHER]

The ESA Rosetta mission, launched in 2004 March, will flyby the second asteroid target (21) Lutetia in 2010 July. This asteroid is quite different from (2867) Steins, encountered by Rosetta in 2008 September. Lutetia is in fact a much larger asteroid, approximately 100 km of diameter, as compared to the 5 km of Steins and also its surface composition seems fairly different. A wide international ground-based observational campaign has been carried out and is still going on to obtain information on the object. In this context, we observed Lutetia four times spectroscopically in the visible region totally covering its rotational period. In this paper we have compared all our observations, in order to try to shed more light on its nature. Moreover, an analysis of the geometric configuration of Lutetia during the several observations has also been performed. Our paper points out small variations of reflectance over the surface, possibly due to a large crater. However, the nature of Lutetia remains still elusive, probably because it could be a transition object between X and C taxonomic classes, pointing out to the crucial values of the forthcoming flyby to clarify the situation. Therefore, all the information we have gathered and here discussed have been very useful also to better define the observational strategy of the asteroid by Rosetta. [ABSTRACT FROM AUTHOR]

Background. Abacavir-lamivudine and tenofovir DF-emtricitabine fixed-dose combinations are commonly used as first-line antiretroviral therapies. However, few studies have comprehensively compared their relative safety profiles. Methods. In this European, multicenter, open-label, 96-week study, antiretroviral-naive adult subjects with human immunodeficiency virus (HIV) infection were randomized to receive either abacavir-lamivudine or tenofovir- emtricitabine with efavirenz. Primary analyses were conducted after 48 weeks of treatment. Bone mineral density (BMD), a powered secondary end point, was assessed by dual energy x-ray absorptiometry. Bone turnover markers (osteocalcin, procollagen 1 N-terminal propeptide, bone specific alkaline phosphatase, and type 1 collagen cross-linked C telopeptide [CTx]) were assessed in an exploratory analysis. Results. A total of 385 subjects were enrolled in the study. BMD loss was observed in both treatment groups, with a significant difference in the change from baseline in both total hip (abacavir-lamivudine group, -1.9%; tenofovir-emtricitabine group, -3.6%; P < .001) and lumbar spine (abacavir-lamivudine group, -1.6%; tenofoviremtricitabine group, -2.4%; P = .036). BMD loss of ⩾6% was more common in the tenofovir-emtricitabine group (13% of the tenofovir-emtricitabine group vs 3% of the abacavir-lamivudine group had a loss of ⩾6% in the hip; 15% vs 5% had a loss of ⩾6% in the spine). Bone turnover markers increased in both treatment groups over the first 24 weeks, stabilizing or decreasing thereafter. Increases in all markers were significantly greater in the tenofovir-emtricitabine treatment group than in the abacavir-lamivudine group at week 24. All but CTx remained significantly different at week 48 (eg, osteocalcin: abacavir-lamivudine group, +8.07 mg/L; tenofovir-emtricitabine group, +11.92 mg/L; P < .001). Conclusions. This study demonstrated the impact of first-line treatment regimens on bone. Greater increases in bone turnover and decreases in BMD were observed in subjects treated with tenofovir-emtricitabine than were observed in subjects treated with abacavir-lamivudine. [ABSTRACT FROM AUTHOR]

The article discusses the result of a study which investigated the role of vitamin D deficiency and calcium-sensing receptor polymorphisms in persistent vertebral fractures and secondary hyperparathyroidism (SHPT) in kidney transplantation. It was found that low 25-vitamin D is involved in the pathogenesis of SHPT and it is a common feature after kidney transplantation. The study also suggests that high parathyroid hormone level is associated with an increased risk for vertebral fractures.

Objectives: To understand the dynamic viral evolution observed during failure on raltegravir-containing regimens, we studied the genotypic and phenotypic patterns of resistance to raltegravir and the residual replication capacity (rRC) of HIV-1 variants selected in vivo. [ABSTRACT FROM PUBLISHER]

BENCHMRK-1 and -2 are ongoing double-blind phase III studies of raltegravir in patients experiencing failure of antiretroviral therapy with triple-class drug-resistant human immunodeficiency virus infection. At week 96 (combined data), raltegravir (400 mg twice daily) plus optimized background therapy was generally well tolerated, with superior and durable antiretroviral and immunological efficacy, compared with optimized background therapy alone. [ABSTRACT FROM AUTHOR]

Free cooling is sometimes useful to face up not only ventilation load but also cooling load as well, taking advantage, directly or indirectly, of the enthalpy difference between inside and outside air in summer. The paper reports on the analysis of the energetic advantage of direct and indirect evaporative cooling (IEC) techniques conducted in summer in different European climates, in which external air flow is established by outdoor, indoor and inlet air enthalpies comparison. Psychrometric diagram has been divided into seven zones as a function of external air conditions; for each zone outside air flow control logic and obtainable free cooling effect have been developed and evaluated. As a function of indoor conditions, outdoor conditions (expressed hourly by Typical Meteorological Year), inlet temperature, external ventilation air flow and building cooling load, energy savings with free cooling techniques have been calculated, considering water consumptions in the adiabatic saturators. Interaction of free cooling, sensible heat recovery and IEC allows very interesting seasonal cooling load reductions, with the additional advantage of decreasing the chiller cooling capacity. All the energetic advantages have been evaluated by an economic point of view, in terms of net present worth and discounted payback period of the investment. [ABSTRACT FROM PUBLISHER]

It is known that near-Earth objects (NEOs) during their orbital evolution may often undergo close approaches to the Sun. Indeed it is estimated that up to ∼70 per cent of them end their orbital evolution colliding with the Sun. Starting from the present orbital properties, it is possible to compute the most likely past evolution for every NEO, and to trace its distance from the Sun. We find that a large fraction of the population may have experienced in the past frequent close approaches, and thus, as a consequence, a considerable Sun-driven heating, not trivially correlated to the present orbits. The detailed dynamical behaviour, the rotational and the thermal properties of NEOs determine the exact amount of the resulting heating due to the Sun. In the present paper, we discuss the general features of the process, providing estimates of the surface temperature reached by NEOs during their evolution. Moreover, we investigate the effects of this process on meteor-size bodies, analysing possible differences with the NEO population. We also discuss some possible effects of the heating which can be observed through remote sensing by ground-based surveys or space missions. [ABSTRACT FROM AUTHOR]

PhotoVoltaic/Thermal cogeneration (PV/T) technology seems to offer very interesting prospects, also considering recent economic incentives on renewable energies issued in Italy. Conversely, some problems have to be faced: good thermal behaviour of the module studying the best thermal exchange between the solar cells and the channelled plate below, selection of the best working temperature according to the need of the plant served by the solar modules, and selection of the best fluid to remove heat. This paper reports on the first results of a survey on electrical and thermal efficiency of some PV/T prototypes, carried out at the experimental testing rig built in Vicenza, varying some parameters (solar radiation, water flow, inlet water temperature). Experimental measurements show very different results for the three PV/T collectors tested. For a particular collector a simulation model has been developed, based on a detailed analytical model, and simulated results have been compared to experimental results. [ABSTRACT FROM AUTHOR]

This paper reports on the energetic and economic comparison between electronic and thermostatic expansion valves in a centralized refrigeration plant of a supermarket. Adopting electronic expansion valves enables an appreciable energy saving, due to the fact that electronic valves allow a lower condensation pressure in systems equipped with air cooled condensers, which is adjusted to variations in outside air temperature. Furthermore, superheating at the evaporator is lower and more stable, increasing cooling capacity and decreasing refrigerant temperature at the compressor discharge (the latter ensures better efficiency and lower wear and tear for the compressor). This study is supported by experimental work where the cabinets of a supermarket, located in the northern Italy, have been equipped with both thermostatic and electronic expansion valves, alternatively activated by solenoid valves on a daily basis, in order to compare the two systems in the same environment and at similar load conditions. This allowed the building of a simulation model of the application to evaluate the performance, energy and economic savings in different climates (the energetic analysis considers total electricity consumptions – compressors, fans and electrical switchboards). [ABSTRACT FROM AUTHOR]

In the present paper the energy impact of buildings' insulation materials in Italy is analyzed, taking into account both the savings in the annual climatisation and the energy consumed to produce them (Life Cycle Assessment, LCA); furthermore the economic matter is evaluated in an investment analysis (Life Cycle Cost, LCC). [ABSTRACT FROM AUTHOR]

Some schemes of operating plants are reported analysing the role of the storage and the sizing of the solar section and absorption chiller together with recorded results. After considering some schemes described in the literature, a hot and cold storage tank system designed by the author is presented. First of all layout and control logic are detailed, then experimental data recorded on the plant are illustrated concerning the seasonal performance both of the solar section and of the absorption chiller. [ABSTRACT FROM AUTHOR]

The most suitable technology for solar cooling by solar thermal collectors is absorption. The final result does not only depend on the choice of a good machine and efficient thermal collectors. Similar collectors and machines can give rise to completely different seasonal performances of the plant. To begin with the load is seldom in phase with solar energy availability. A hot storage system must be provided. It cannot, however, be sized with solar heating criteria as useful thermal differences are completely different. Moreover it is usually unwise to size the absorption chiller on the solar power input for reason of cost: a cold storage system is often suggested as the cooling capacity control at the chiller level can be very inefficient. [ABSTRACT FROM AUTHOR]

Background. Initiation of antiretroviral therapy during primary human immunodeficiency virus (HIV)-1 infection may confer long-term benefit. Methods. After initiation of zidovudine, lamivudine, abacavir, and amprenavir therapy in patients in the QUEST cohort, predictors of virological outcome, virological and immunological changes, and adverse events were evaluated over 48 weeks. Results. One hundred forty-eight patients started antiretroviral therapy during primary HIV-1 infection with ⩽3 bands on Western Blot (median plasma HIV-1 RNA load, 5.4 log copies/mL; median CD4 cell count, 517 cells/mm3). By week 48, 36% of patients had stopped treatment or were lost to follow-up. Among the 115 patients receiving follow-up care at week 48 (102 of whom were receiving antiretroviral therapy), the median viral load decrease was -5.4 log copies/mL (interquartile range [IQR], -6.4 to -3.9 log copies/mL), and the median increase in CD4 cell count was 147 cells/mm³ (IQR, -1 to 283 cells/mm3); 84.2% of patients had a viral load ⩽50 copies/mL, and 44.7% of patients had a viral load ⩽3 copies/mL. The median cell-associated RNA level decreased from 3.4 log copies/million PBMCs (IQR, 2.9–4.1 log copies/million PBMCs) to 0.8 log copies/million PBMCs (IQR, 0.5–1.4 log copies/million PBMCs), and the median cell-associated DNA level decreased from 2.8 log copies/million PBMCs (IQR, 2.4–3.0 log copies/million PBMCs) to 1.6 log copies/million PBMCs (IQR, 1.2–1.9 log copies/million PBMCs); 33.3% of patients had an undetectable RNA level, and 9.5% of patients had an undetectable cell-associated DNA level. The median CD8+/CD38++ T cell count decreased from 459 cells/mm³ (IQR, 208–974 cells/mm³) to 33 cells/mm³ (IQR, 19–75 cells/mm³). Baseline CD8+/CD3 8++ T cell count and cell-associated DNA level were independent inverse predictors for reaching a viral load ⩽3 copies/mL. Eighty-three patients experienced a serious adverse event (median duration of an adverse event, 15 days). Conclusions. Initiation of antiretroviral therapy during primary HIV-1 infection was associated with very significant antiretroviral activity and a decrease in immune activation. Lower baseline CD8+/CD38++ T cell count and cell-associated DNA level were predictive of achieving a viral load ⩽3 copies/mL. [ABSTRACT FROM AUTHOR]

It is estimated that about 140 million heat pumps are working in the world. This evidences that the equipment conceived by Lord Kelvin back in 1852 has finally penetrated into the market. In the last 20 years the heat pump has improved both regarding the thermal exchange surfaces, the compressor, and the control and defrosting systems. Thus not only was the COP strongly improved but also seasonal performances. Further equipment improvements are aimed to better exploit the properties of new refrigerants, utilising even the pressure drop between condenser and evaporator, usually dissipated by throttling. Gas driven heat pumps were also improved with higher efficiency i.c. motors and much longer maintenance intervals. Absorption heat pumps are now available in many different models suitable to different applications. Probably most improvements took place with lower heating temperatures and the use of cold sources more suitable than the outside air, above all surface and underground water, the ground and the recovery in mechanical ventilation systems. [ABSTRACT FROM AUTHOR]